User profiles for Panayiotis Koufargyris

Panagiotis Koufargyris

National and Kapodistrian University of Athens, Medical School
Verified email at med.uoa.gr
Cited by 3217

[HTML][HTML] Effect of anakinra on mortality in patients with COVID-19: a systematic review and patient-level meta-analysis

…, S Ktena, M Tsilika, P Koufargyris… - The Lancet …, 2021 - thelancet.com
Background Anakinra might improve the prognosis of patients with moderate to severe
COVID-19 (ie, patients requiring oxygen supplementation but not yet receiving organ support). …

[PDF][PDF] Complex immune dysregulation in COVID-19 patients with severe respiratory failure

…, I Koutsodimitropoulos, D Velissaris, P Koufargyris… - Cell host & …, 2020 - cell.com
Proper management of COVID-19 mandates better understanding of disease pathogenesis.
The sudden clinical deterioration 7–8 days after initial symptom onset suggests that severe …

[HTML][HTML] Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 …

…, V Tzavara, E Kostis, L Dagna, P Koufargyris… - Nature medicine, 2021 - nature.com
Early increase of soluble urokinase plasminogen activator receptor (suPAR) serum levels is
indicative of increased risk of progression of coronavirus disease 2019 (COVID-19) to …

[PDF][PDF] Activate: randomized clinical trial of BCG vaccination against infection in the elderly

…, T Gkavogianni, ME Adami, G Damoraki, P Koufargyris… - Cell, 2020 - cell.com
BCG vaccination in children protects against heterologous infections and improves survival
independently of tuberculosis prevention. The phase III ACTIVATE trial assessed whether …

Serum hydrogen sulfide and outcome association in pneumonia by the SARS-CoV-2 coronavirus

…, G Dimopoulos, M Lada, P Koufargyris… - Shock, 2020 - journals.lww.com
Background: The pneumonia of COVID-19 illness has often a subtle initial presentation making
mandatory the use of biomarkers for evaluation of severity and prediction of final patient …

[HTML][HTML] A 6-mRNA host response classifier in whole blood predicts outcomes in COVID-19 and other acute viral infections

…, S Munoz, C Herrero, N Antonakos, P Koufargyris… - Scientific Reports, 2022 - nature.com
Predicting the severity of COVID-19 remains an unmet medical need. Our objective was to
develop a blood-based host-gene-expression classifier for the severity of viral infections and …

[HTML][HTML] Early start of oral clarithromycin is associated with better outcome in COVID-19 of moderate severity: the ACHIEVE open-label single-arm trial

…, E Klouras, K Katrini, P Koufargyris… - Infectious Diseases and …, 2021 - Springer
Introduction The anti-inflammatory effect of macrolides prompted the study of oral clarithromycin
in moderate COVID-19. Methods An open-label non-randomized trial in 90 patients with …

[HTML][HTML] BioFire® FilmArray® Pneumonia Panel for Severe Lower Respiratory Tract Infections: Subgroup Analysis of a Randomized Clinical Trial

…, L Liaskou-Antoniou, P Koufargyris… - Infectious Diseases and …, 2021 - Springer
Introduction The epidemiology of severe lower respiratory tract infections (LRTI) is constantly
changing. We aimed to describe it using the BioFire ® FilmArray ® Pneumonia plus (PNplus…

[HTML][HTML] Host cystathionine-γ lyase derived hydrogen sulfide protects against Pseudomonas aeruginosa sepsis

G Renieris, DE Droggiti, K Katrini, P Koufargyris… - PLoS …, 2021 - journals.plos.org
Hydrogen sulfide (H 2 S) has recently been recognized as a novel gaseous transmitter with
several anti-inflammatory properties. The role of host- derived H 2 S in infections by …

Author correction: early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled …

…, V Tzavara, E Kostis, L Dagna, P Koufargyris… - Nature Medicine, 2021 - nature.com
Panagiotis Koufargyris … Evdoxia Kyriazopoulou, Christina Damoulari, Maria Tsilika,
Panagiotis Koufargyris, Konstantina Katrini, Sofia Ktena, Maria Mouktaroudi, Antigone …